InterCure Ltd. (INCR:NASDAQ) closed at $4.53 on October 23, 2026, up 1.34% on the day. The stock trades 40.4% below its 52-week high of $7.60 and 33.2% above its 52-week low of $3.40. InterCure Ltd. is part of the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch).
In 252 trading sessions since October 23, 2025, INCR closed higher on 107 days (42%). Its best day was March 9, 2026 (+400.00%) and its worst was June 1, 2026 (-10.83%). The stock moved 10% or more in a single session 9 times. It opened at least 5% above the previous day's high 5 times.
INC Research Holdings, Inc., a contract research organization, provides various clinical development services for the biopharmaceutical and medical device industries in North America, Europe, the Middle East and Africa, the Asia-Pacific, and Latin America. The company offers a range of services focusing on Phase I to Phase IV clinical trials in central nervous system, oncology, and other complex therapeutic areas. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, and regulatory and medical writing; and data services consisting of clinical data management, electronic data capture, and biostatistics. The company's services also comprise strategic and regulatory services, including strategic development services, regulatory consulting and submissions, clinical operations optimization, and pricing and reimbursement planning; and real world and late stage services, such as specialized support for patient registries, safety surveillance studies, prospective observational studies, health outcome research, patient reported outcomes,...
Find more stocks like INCR with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.